Case 1. A 61-year-old woman had cGVHD-related
dry eye that resisted traditional medications. Next, we use topical
diquafosol in addition to conventional treatments. The patient used
diquafosol for 6 months without experiencing any side effects. The symptoms, including
dry-eye sensation, ocular
pain,
foreign body sensation, and
photophobia, as well as ocular surface findings including
fluorescein and
rose bengal scores and tear break-up time (TBUT), partly improved. To further improve the clinical signs and symptoms and decrease chronic
inflammation,
rebamipide was added to
diquafosol. The symptoms, TBUT, and
fluorescein and
rose bengal scores markedly improved after long-term dual treatment without any side effects for 6 months. Case 2. A 77-year-old woman had OCP-like disease with
dry eye. The patient did not improve using the currently available conventional treatments. Next, we use topical
rebamipide in addition to conventional treatments. Symptoms including
asthenopia,
dry-eye sensation, ocular
pain, and dull sensation, as well as
fluorescein and
rose bengal scores and TBUT, partly improved. Specifically, functional visual acuity was markedly improved after commencement of
rebamipide. To further improve the clinical signs and symptoms and increase tear film stability and tear film volume,
diquafosol was added to
rebamipide. The combination of
diquafosol and
rebamipide worked for the patient. Improvements were seen in several symptoms,
fluorescein and
rose bengal scores, Schirmer test value, and TBUT without any side effects for 12 months.
CONCLUSIONS: